WO2002089816A1 - Methode d'administration de bisphosphonates par inhalation pour traiter ou prevenir la resorption osseuse et l'osteoporose - Google Patents

Methode d'administration de bisphosphonates par inhalation pour traiter ou prevenir la resorption osseuse et l'osteoporose Download PDF

Info

Publication number
WO2002089816A1
WO2002089816A1 PCT/EP2002/004821 EP0204821W WO02089816A1 WO 2002089816 A1 WO2002089816 A1 WO 2002089816A1 EP 0204821 W EP0204821 W EP 0204821W WO 02089816 A1 WO02089816 A1 WO 02089816A1
Authority
WO
WIPO (PCT)
Prior art keywords
bisphosphonic acid
acid
amino
alendronate
pharmaceutically acceptable
Prior art date
Application number
PCT/EP2002/004821
Other languages
English (en)
Inventor
Nageswara R. Palepu
Original Assignee
Novartis Ag
Novartis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag, Novartis Pharma Gmbh filed Critical Novartis Ag
Priority to DE60212621T priority Critical patent/DE60212621T2/de
Priority to BR0209360-0A priority patent/BR0209360A/pt
Priority to EP02769132A priority patent/EP1392325B1/fr
Priority to JP2002586951A priority patent/JP2004528365A/ja
Priority to CA002444718A priority patent/CA2444718A1/fr
Publication of WO2002089816A1 publication Critical patent/WO2002089816A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/04—Drugs for disorders of the urinary system for urolithiasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis

Definitions

  • the present invention relates to the treatment and prevention of bone diseases in humans, including osteoporosis in postmenopausal women, Paget's Disease and hypercalcemia, by administration of a bisphosphonate in an inhalation form.
  • the invention also relates to pharmaceutical inhalation compositions suitable for the treatment and prevention of bone diseases.
  • Bisphosphonates are known in the art as bone resorption inhibitors.
  • Examples of bisphosphonates include, alendronate, 4-amino-1-hydroxybutylidene-1,1 - bisphosphonic acid; tiludronate, 4-chlorophenylthiomethylene bisphosphonatic acid; pamidronate, (3-amino-hydroxypropylidnen) bisphosphonic acid; etidronate, (1- hydroxyethylidene)bisphosphonic acid; residronate, 1-hydroxy-2-(3-pyridinyl)ethylidene bisphosphonic acid; zoledronate, 2-(imidazol-1-yl)-1-hydroxyethane-1,1-bisphosphonic acid; and the pharmaceutically acceptable salts of the above compounds.
  • Bisphosphonates are useful in the treatment and prevention of bone diseases such as osteoporosis. Specifically, bisphosphonates are useful for the treatment of urolithiasis and are capable of inhibiting bone reabso ⁇ tion. Bisphosphonates are also useful in lessening the risk of non-vertebral fractures in osteoporotic women and as a therapeutic agent for hypercalcemia and Paget's disease.
  • Bisphosphonates may also be administered by intravenous methods.
  • the benefits of bisphosphonates are observed by its effect on bone mass and density.
  • oral and intravenous dosage forms have very low bioavailability. In some instances, the bioavailability is less than 1 %. Accordingly, it would be desirable to find a route of administration of bisphosphonates that substantially increases its bioavailability.
  • oral dosage forms of the free acid form of certain bisphosphonates e.g. 4- amino-1-hydroxybutylidene-1,1 -bisphosphonic acid, may result in gastric irritability, and therefore it would also be desirable to administer these bisphosphonates by a route that avoids such gastrointestinal problems.
  • Figure 1 shows a plot of Plasma disintegrations per minute ("DPM") following intratracheal administration of 250 ⁇ g if alendronate to rats.
  • DPM Plasma disintegrations per minute
  • FIG. 2 shows a plot of Plasma disintegrations per minute ("DPM") following intravenous administration of 250 ⁇ g if alendronate to rats.
  • DPM Plasma disintegrations per minute
  • Figure 3 shows the percent drug release verses time in pH 6.8 phosphate and 0.1 N HCI for alendronate beads.
  • Figure 4 shows the percent drug release verses time in pH 6.8 phosphate and 0.1 N HCI for alendronate beads coated with an enteric polymer.
  • the present invention relates to the treatment and prevention of osteoporosis in postmenopausal women, and the treatment of urolithiasis and the inhibition of bone reabsorption, by administration of a bisphosphonate in an inhalation form.
  • the invention also relates to inhalation compositions suitable for the treatment of and prevention of osteoporosis in postmenopausal women, and the treatment of urolithiasis and the inhibition of bone reabsorption.
  • bisphosphonates of the present invention include alendronate, 4- amino-1-hydroxybutylidene-1,1 -bisphosphonic acid; tiludronate, 4-chlorophenyl thiomethylene bisphosphonatic acid; pamidronate, (3-amino-hydroxypropylidnen) bisphosphonic acid; etidronate, (l-hydroxyethylidene)bisphosphonic acid; residronate, 1- hydroxy-2-(3-pyridinyl)ethylidene bisphosphonic acid; zoledronate, 2-(imidazol-1-yl)-1- hydroxyethane-1,1 -bisphosphonic acid; and the pharmaceutically acceptable salts of the above compounds.
  • the pharmaceutically acceptable salts of the above bisphosphonic acids include salts of alkali metals (e.g., Na, K), alkali earth metals (e.g., Ca), salts of inorganic acids, such as HCI and salts of organic acids such as citric acid and amino acids.
  • alkali metals e.g., Na, K
  • alkali earth metals e.g., Ca
  • salts of inorganic acids such as HCI
  • salts of organic acids such as citric acid and amino acids.
  • Sodium salt forms are preferred.
  • alendronate the monosodium salt trihydrate form is most preferred.
  • alendronate may be administered in its anhydrous form.
  • Bisphosphonate formulations of the present invention are administered in an inhalation dosage form directly into the respiratory tract.
  • Bisphosphonate compounds may be administered by any of the methods and formulations employed in the art for inhalation administration. Such methods include metered dose, nebulizers, breath activated or powder.
  • the route of administration is in a powder form.
  • the active ingredient may be used as a powder with a particle size of 1 to 10 micrometers, preferably 2-8 micrometers.
  • the particle size of the powder should desirably be no greater than 100 microns diameter, since larger particles may clog the valve or orifice of the container.
  • the particle size of the finely-divided solid powder should for physiological reasons be less than 25 microns and preferably less than about 10 microns in diameter.
  • the particle size of the powder for inhalation therapy should most preferably be in the range of 2 to 10 microns.
  • particle size there is no lower limit on particle size except that imposed by the intended use of the produced.
  • the lower limit of particle size is that which will be readily absorbed and retained on or in body tissues. When particles of less than about one-half micron in diameter are administered by inhalation they tend to be exhaled by the patient.
  • the concentration of medicament depends upon the desired dosage but is generally in the range 0.01 to 5% by weight.
  • a preferred dosage in inhalation form would be 50-100 micrograms per day and administration of the inhalation composition would be on a once a day or once a week schedule.
  • the precise therapeutic dosage amount will depend on the age, size, sex and condition of the subject, the nature and severity of the disorder, and other such factors. An ordinarily skilled physician or clinician can readily determine and prescribe the effective amount of the drug required for a particular patient.
  • the propellant generally comprises a mixture of liquified chlorofluorocarbons (CFCs) which are selected to provide the desired vapor pressure and stability of the formulation.
  • CFCs chlorofluorocarbons
  • Propellants 11, 12 and 114 are the most widely used propellants in aerosol formulations for inhalation administration.
  • Other commonly used propellants include Propellants 113, 142b, 152a 124, and dimethyl ether.
  • the compound 1,1,1 ,2- tetrafluoroethane is also a commonly used propellant for medicinal aerosol formulations.
  • the propellant comprises 40 to 90% by weight of the total inhalation composition.
  • the inhalation composition may also contain dispersing agents and solvents, such as methylene chloride, ethanol or phosphate buffer solution (PBS).
  • dispersing agents such as methylene chloride, ethanol or phosphate buffer solution (PBS).
  • surfactants have also been used as dispersing agents.
  • agents include sorbitan tiroleate, oleyl alcohol, oleic acid, lecithin or oils derived from natural sources, such as, corn oil, olive oil, cotton seed oil and sunflower seed oil are useful in keeping the suspended particles form agglomerating.
  • the surface active agents are generally present in amounts not exceeding 5 percent by weight of the total formulation. They will usually be present in the weight ratio 1:100 to 10:1 surface active agent to bisphosphonate, but the surface active agent may exceed this weight ratio in cases where the drug concentration in the formulation is very low.
  • the powder inhalation composition of this embodiment of the present invention may also comprise a lubricant such as isopropyl myristate, light mineral oil or other substances which provide slippage between particles of the compound as well as lubrication for component parts of the valve of the inhalation device.
  • a lubricant such as isopropyl myristate, light mineral oil or other substances which provide slippage between particles of the compound as well as lubrication for component parts of the valve of the inhalation device.
  • the inhalation formulation of the present invention can be delivered in any conventional inhalation device employed in the art for the administration of a medicinal compound.
  • the bisphosphonate can be administered into the respiratory tract by any inhalation form known in the art.
  • the active ingredient is typically administered in admixture with suitable pharmaceutical diluents, excipients or carriers.
  • suitable binders, lubricants, disintegrating agents and coloring agents can also be incorporated into the mixture of active ingredient(s) and inert carrier materials.
  • suitable binders may include starch, gelatin, natural sugars such as glucose, anhydrous lactose, free-flow lactose, beta-lactose, and corn sweeteners, natural and synthetic gums, such as acacia, tragacanth or sodium alginate, carboxymethyl cellulose, polyethylene glycol, waxes, cross carmallose sodium, and the like.
  • Lubricants used in these dosage forms include sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride and the like.
  • alendronate particles can be coated with an enteric coated polymer so that the drug will not be released until it reaches the small intestine. Once the drug is released in the small intestine, it will not return to the esophagus during the reflux reaction.
  • the active ingredient, alendronate can be coated with enteric polymers including sureteric, cellulose acetate phthalate, methacrylic acid copolymer, hydroxypropyl methylcellulose phthalate, aquacoat ECD 30, shellac and zein.
  • enteric polymers including sureteric, cellulose acetate phthalate, methacrylic acid copolymer, hydroxypropyl methylcellulose phthalate, aquacoat ECD 30, shellac and zein.
  • 14 C-alendronate sodium is obtained from Chemsyn Science Laboratories and stored frozen at -80°C. Prior to use, the solution is diluted using PBS to make a dosing solution.
  • Sprague-Dawley rats with jugular and femoral vein catheters from Hilltop are used. Each rat weighs between 250-300 grams.
  • Each rat in the i.t. dose group is anesthetized for about 5 minutes with isoflurane anesthetic (oxygen with 3.0 to 5.0% isoflurane).
  • Each rat is vertically held by hanging its upper jaw to a rubber band which is stretched using two burette stands.
  • the i.t. dose is administered by a blunt stainless steel needle for intratracheal instillation with a gavage needle inserted in through the mouth into the trachea just above the main carina.
  • the rats in the i.v. group receive similar anesthesia treatment.
  • Blood samples are collected from the jugular or cephalic vein at predose (2 to 0.25 hours prior to dosing), 0.5, 1, 2, 2.5, 3, 4, 8, 12 and 16 hours postdose for both groups.
  • the samples are analyzed for 14 C-alendronate in a scintillation counter to determine the maximum blood concentration (C MA ⁇ ), time to maximum blood concentration (T AX ), area under the blood concentration vs. time curve (AUC), and terminal half-life (t 1 ⁇ ).
  • C MA ⁇ maximum blood concentration
  • T AX time to maximum blood concentration
  • AUC area under the blood concentration vs. time curve
  • t 1 ⁇ terminal half-life
  • AUC(O- ⁇ ) Area under the plasma concentration time curve extrapolated to infinite time
  • the mean C M AX of alendronate following i.t. administration was 9501 DPM/sample with a mean T MAX of 0.5 hours.
  • the bioavailability of the i.t. dose relative to the i.v. dose of alendronate was 114%.
  • Plasma concentrations verses time are shown in Figures 1 and 2. Three of the rates in the i.t. group did not receive the dose to the lung, but rather to the stomach; the results for these rats is shown as the dashed line at the bottom of Figure 1.
  • alendronate was coated with Eudragit L-30D-55, a enteric polymer comprising methacrylic acid copolymer.
  • the following formulations were prepared:
  • Alendronate beads Form I 754.955 mg/g
  • Uncoated alendronate beads were prepared by dissolving povidone and alendronate sodium in purified water. Talc was suspended in purified water and the solution and suspension were combined. The povidone, alendronate sodium and talc suspension were sprayed onto the Nu-Parelis. The uncoated alendronate beads were screened.
  • the finished alendronate enteric coated beads along with uncoated beads were tested for dissolution as a function of time.
  • the dissolution results showed that the uncoated alendronate beads released in 0.1 N HCI and in pH 6.8 phosphate buffer.
  • the enteric coated alendronate beads had no drug release for 2 hours in 0.1 N HCI and showed similar drug release to the uncoated beads in pH 6.8 phosphate buffer.
  • Graphs of the dissolution testing can be found in the Figures 3 and 4. The results show that alendronate can be enteric coated so that drug release is stopped in 0.1 N HCI and then released in pH 6.8 phosphate buffer.

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne le traitement et la prévention de maladies osseuses chez les humains, notamment l'ostéoporose chez les femmes postménopausées, la maladie osseuse de Paget et l'hypocalcémie, par administration d'un bisphosphonate sous forme d'inhalation. L'invention concerne également des compositions pharmaceutiques d'inhalation appropriées pour traiter et prévenir ces maladies osseuses.
PCT/EP2002/004821 2001-05-02 2002-05-02 Methode d'administration de bisphosphonates par inhalation pour traiter ou prevenir la resorption osseuse et l'osteoporose WO2002089816A1 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
DE60212621T DE60212621T2 (de) 2001-05-02 2002-05-02 Verabreichung von bisphosphonaten durch inhalation zur behandlung von knochenresorption und osteoporosis
BR0209360-0A BR0209360A (pt) 2001-05-02 2002-05-02 Método de administração de bisfosfonatos por inalação no tratamento ou prevenção de reabsorção óssea e osteoporose
EP02769132A EP1392325B1 (fr) 2001-05-02 2002-05-02 Methode d'administration de bisphosphonates par inhalation pour traiter ou prevenir la resorption osseuse et l'osteoporose
JP2002586951A JP2004528365A (ja) 2001-05-02 2002-05-02 骨再吸収症および骨粗しょう症の処置または予防におけるビスホスホネートの吸入投与方法
CA002444718A CA2444718A1 (fr) 2001-05-02 2002-05-02 Methode d'administration de bisphosphonates par inhalation pour traiter ou prevenir la resorption osseuse et l'osteoporose

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US84782701A 2001-05-02 2001-05-02
US09/847,827 2001-05-02

Publications (1)

Publication Number Publication Date
WO2002089816A1 true WO2002089816A1 (fr) 2002-11-14

Family

ID=25301603

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2002/004821 WO2002089816A1 (fr) 2001-05-02 2002-05-02 Methode d'administration de bisphosphonates par inhalation pour traiter ou prevenir la resorption osseuse et l'osteoporose

Country Status (11)

Country Link
US (2) US6743414B2 (fr)
EP (1) EP1392325B1 (fr)
JP (1) JP2004528365A (fr)
CN (1) CN100345549C (fr)
AT (1) ATE330616T1 (fr)
BR (1) BR0209360A (fr)
CA (1) CA2444718A1 (fr)
DE (1) DE60212621T2 (fr)
ES (1) ES2268086T3 (fr)
PT (1) PT1392325E (fr)
WO (1) WO2002089816A1 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8399023B2 (en) 2009-07-31 2013-03-19 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
US9169279B2 (en) 2009-07-31 2015-10-27 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
US9340565B2 (en) 2010-11-24 2016-05-17 Thar Pharmaceuticals, Inc. Crystalline forms
US10093691B2 (en) 2009-07-31 2018-10-09 Grunenthal Gmbh Crystallization method and bioavailability
US10195218B2 (en) 2016-05-31 2019-02-05 Grunenthal Gmbh Crystallization method and bioavailability

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR200300510A2 (tr) * 2003-04-18 2004-11-22 Sanovel �La� Sanay� Ve T�Caret A.�. Dağılan alendronat mikropartikül formülasyonu
ZA200900603B (en) * 2006-11-21 2010-05-26 Teikoku Pharma Usa Inc Biphosphonate inhalant formulations and methods for using the same
US20080182823A1 (en) * 2007-01-26 2008-07-31 Hidesmasa Katsumi Polymer-linked-biophosphonate inhalant formulations and methods for using the same
US20100034752A1 (en) * 2008-08-11 2010-02-11 Toru Hibi Inhalant formulations comprising a bisphosphonate and a pyrazolone derivative and methods for using the same
CN105640924B (zh) * 2016-01-18 2018-11-02 杭州旦杰医学科技有限公司 用于呼吸道给药的阿仑膦酸钠粉雾剂及其制备方法和用途
CN111053761B (zh) * 2020-01-16 2022-05-03 杭州旦承医药科技有限公司 一种吸入用双膦酸类药物及其制备方法及其在慢性阻塞性肺疾病的用途

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5958907A (en) * 1995-06-02 1999-09-28 The University Of Iowa Research Foundation Pharmaceutical compositions and uses of inorganic pyrophosphates
WO2000027359A1 (fr) * 1998-11-12 2000-05-18 Pilkiewicz Frank G Systeme d'inhalation
WO2001082903A1 (fr) * 2000-04-28 2001-11-08 Lipocine, Inc. Preparation gastro-resistante de composes d'acide bisphosphonique et methodes therapeutiques associees
WO2002009631A1 (fr) * 2000-07-27 2002-02-07 Umd, Inc. Administration de diphosphonates par voie vaginale

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE182C (de) * 1877-08-02 A. LANGE & SÖHNE in Glashütte, Sachsen Sekundenwerk mit springendem Zeiger
US4405598A (en) * 1976-01-30 1983-09-20 Fisons, Limited Composition for treating asthma
IT1201087B (it) * 1982-04-15 1989-01-27 Gentili Ist Spa Bifosfonati farmacologicamente attivi,procedimento per la loro preparazione e relative composizioni farmaceutiche
US5225183A (en) * 1988-12-06 1993-07-06 Riker Laboratories, Inc. Medicinal aerosol formulations
US5183815A (en) * 1991-01-22 1993-02-02 Merck & Co., Inc. Bone acting agents
WO1993009785A1 (fr) * 1991-11-22 1993-05-27 Procter & Gamble Pharmaceuticals, Inc. Compositions de risedronate a liberation lente
US5358941A (en) * 1992-12-02 1994-10-25 Merck & Co., Inc. Dry mix formulation for bisphosphonic acids with lactose
DE59309360D1 (de) * 1992-12-02 1999-03-18 Hoechst Ag Guanidinalkyl-1, 1-bisphosphonsäurederivate, Verfahren zu ihrer Herstellung und ihre Verwendung
US5431920A (en) * 1993-09-21 1995-07-11 Merck Frosst, Canada, Inc. Enteric coated oral compositions containing bisphosphonic acid antihypercalcemic agents
JPH10504839A (ja) * 1995-02-17 1998-05-12 メルク エンド カンパニー インコーポレーテッド 非脊椎骨折のリスクを減少させる方法
IL118422A0 (en) * 1995-06-02 1996-09-12 Merck & Co Inc Use of alendronate for the prevention of osteoporosis
AU5886096A (en) * 1995-06-06 1996-12-24 Merck & Co., Inc. Anhydrous alendronate monosodium salt formulations
DE19615812A1 (de) * 1996-04-20 1997-10-23 Boehringer Mannheim Gmbh Pharmazeutische Zubereitung enthaltend Diphosphonsäuren zur oralen Applikation
PL195272B1 (pl) * 1997-07-22 2007-08-31 Merck & Co Inc Zastosowania kwasu alendronowego lub jego farmaceutycznie dopuszczalnej soli lub ich mieszaniny
DE19828450A1 (de) * 1998-06-26 1999-12-30 Hassan Jomaa Bisphosphonsäuren und deren Derivate enthaltende Arzneimittel zur Prophylaxe und zur Behandlung von Autoimmunkrankheiten sowie von Allergien
US6008207A (en) * 1998-08-13 1999-12-28 Merck & Co., Inc. Anhydrous alendronate monosodium salt formulations
US6414006B1 (en) * 1998-10-15 2002-07-02 Merck Frosst Canada & Co. Methods for inhibiting bone resorption
AU6934600A (en) * 1999-08-27 2001-03-26 Board Of Regents, The University Of Texas System Cd40 ligand and cd40 agonist compositions and methods of use
KR100317935B1 (ko) * 1999-10-20 2001-12-22 유승필 대사성 골질환 치료용 약제조성물 및 이의 제조방법

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5958907A (en) * 1995-06-02 1999-09-28 The University Of Iowa Research Foundation Pharmaceutical compositions and uses of inorganic pyrophosphates
WO2000027359A1 (fr) * 1998-11-12 2000-05-18 Pilkiewicz Frank G Systeme d'inhalation
WO2001082903A1 (fr) * 2000-04-28 2001-11-08 Lipocine, Inc. Preparation gastro-resistante de composes d'acide bisphosphonique et methodes therapeutiques associees
WO2002009631A1 (fr) * 2000-07-27 2002-02-07 Umd, Inc. Administration de diphosphonates par voie vaginale

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8399023B2 (en) 2009-07-31 2013-03-19 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
US8933057B2 (en) 2009-07-31 2015-01-13 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
US9169279B2 (en) 2009-07-31 2015-10-27 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
US9334296B2 (en) 2009-07-31 2016-05-10 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
US10093691B2 (en) 2009-07-31 2018-10-09 Grunenthal Gmbh Crystallization method and bioavailability
US10323052B2 (en) 2009-07-31 2019-06-18 Grunenthal Gmbh Crystallization method and bioavailability
US9340565B2 (en) 2010-11-24 2016-05-17 Thar Pharmaceuticals, Inc. Crystalline forms
US10519176B2 (en) 2010-11-24 2019-12-31 Thar Pharma, Llc Crystalline forms
US10195218B2 (en) 2016-05-31 2019-02-05 Grunenthal Gmbh Crystallization method and bioavailability

Also Published As

Publication number Publication date
EP1392325A1 (fr) 2004-03-03
PT1392325E (pt) 2006-10-31
US20040127466A1 (en) 2004-07-01
CN1505517A (zh) 2004-06-16
CN100345549C (zh) 2007-10-31
US20030064966A1 (en) 2003-04-03
EP1392325B1 (fr) 2006-06-21
ATE330616T1 (de) 2006-07-15
US6743414B2 (en) 2004-06-01
CA2444718A1 (fr) 2002-11-14
BR0209360A (pt) 2004-06-08
DE60212621T2 (de) 2007-06-14
DE60212621D1 (de) 2006-08-03
JP2004528365A (ja) 2004-09-16
ES2268086T3 (es) 2007-03-16

Similar Documents

Publication Publication Date Title
US10323052B2 (en) Crystallization method and bioavailability
US9682091B2 (en) Oral forms of a phosphonic acid derivative
JP6336494B2 (ja) 増強剤を含む固形医薬組成物およびその調製方法
US9169279B2 (en) Crystallization method and bioavailability
JP5415769B2 (ja) 経鼻投与用製剤
US6743414B2 (en) Inhalation administration of biophosphonates
US20140349974A1 (en) Zoledronic acid dosage forms for the treatment of pain
PL180318B1 (pl) oraz sposób wytwarzania preparatu farmaceutycznego odpowiedniegodo nebulizacji zawierajacego propionian flutikazonu PL PL PL PL PL PL
HU227530B1 (en) Delayed-release compositions containing risedronate and process for their production
JPH09512816A (ja) プロテーゼのゆるみ及びプロテーゼの移動を防止するための特定メタンビスホスホン酸誘導体の使用
JP2003500352A (ja) 血管形成を処置するためのビスホスホン酸の使用
US10093691B2 (en) Crystallization method and bioavailability
US7319095B2 (en) Use of GABAB receptor agonists
CA2110110A1 (fr) Utilisation de certains derives de l'acide methanediphosphonique pour le traitement de fractures
JP6908523B2 (ja) ネブライザー用組成物
KR19980703055A (ko) 특정 시스틴 유도체의 약물학적 용도
WO2006071185A1 (fr) Nouvelle utilisation des agonistes du recepteur gabab
JPH08277223A (ja) 高カルシウム血症治療のための薬剤
JPWO2005056019A1 (ja) 悪性黒色腫治療剤

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LT LU LV MA MD MK MN MX NO NZ OM PH PL PT RO RU SE SG SI SK TJ TM TN TR TT UA US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2002769132

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2444718

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 028091388

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 2002586951

Country of ref document: JP

WWP Wipo information: published in national office

Ref document number: 2002769132

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWG Wipo information: grant in national office

Ref document number: 2002769132

Country of ref document: EP